I am probably the first person to bring Point Therapeutics to the discussion. After the data release today I am truly amazed and agree, that non randomized studies mean less than nothing.
In addition, in the talabostat combination trial with docetaxal (Taxotere®: sanofi-aventis), the talabostat arm of the study demonstrated significantly lower overall survival than the placebo arm
Market Data 
Markets 
AI
